[Fierce Webinar] Why high-quality raw materials are vital | Producing therapeutic cardiomyocytes from iPSC stem cells28 Nov 2023
Date and Time
November 28th 2023, 11.00am ET, USA (60 minutes)
Commercializing biopharmaceuticals and advanced therapies requires robust, standardized manufacturing processes. Human serum albumin's multifunctionality makes it ubiquitous in biopharma, but variable ligands occupying binding sites lead to inconsistent quality between batches, complicating process reproducibility. Recombumin® recombinant human albumin (rHA) offers an animal-free and consistent alternative that meets regulatory demands and can accelerate therapies toward patient availability.
In this webinar, Dr Takehiko Kaneko, the Chief Medical Officer of Heartseed, will join Dr Morton, Albumedix’ CTO, to discuss their investigative cardiomyocyte therapies journey from the bench to its current point in phase 1/2 clinical trials.
How to sign up
Sign up to view the webinar here: https://www.fiercebiotech.com/premium/webinar/bringing-new-heart-failure-therapy-clinic
Phil Morton, PhD
Chief Technology Officer, Albumedix Ltd
Dr. Phil Morton has more than 25 years of experience in the biopharmaceutical industry, where he has worked across process development, product development, and product application research. As CTO of Albumedix, Dr. Morton leads a team of specialists to refine recombinant albumin technologies and fully leverage albumin’s multifaceted capabilities.
Dr. Takehiko Kaneko, MD
Chief Medical Officer and Head of R&D, Heartseed Inc.
Dr. Takehiko Kaneko, MD is CMO and head of R&D of Heartseed Inc. Before joining Heartseed, he served on the leadership team at SanBio Co. Ltd., where he was responsible for the development and regulatory standards of cell therapy products. He has also worked in medical affairs at Bristol-Myers Squibb, clinical development at Pfizer, and early development at Novartis. Dr. Kaneko received his medical degree from Keio University School of Medicine.